GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zealand Pharma A/S (OCSE:ZEAL) » Definitions » Cyclically Adjusted PB Ratio

Zealand Pharma A/S (OCSE:ZEAL) Cyclically Adjusted PB Ratio : 26.43 (As of Jun. 01, 2024)


View and export this data going back to 2010. Start your Free Trial

What is Zealand Pharma A/S Cyclically Adjusted PB Ratio?

As of today (2024-06-01), Zealand Pharma A/S's current share price is kr639.50. Zealand Pharma A/S's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 was kr24.20. Zealand Pharma A/S's Cyclically Adjusted PB Ratio for today is 26.43.

The historical rank and industry rank for Zealand Pharma A/S's Cyclically Adjusted PB Ratio or its related term are showing as below:

OCSE:ZEAL' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 3.3   Med: 9.91   Max: 31.77
Current: 26.42

During the past years, Zealand Pharma A/S's highest Cyclically Adjusted PB Ratio was 31.77. The lowest was 3.30. And the median was 9.91.

OCSE:ZEAL's Cyclically Adjusted PB Ratio is ranked worse than
97.55% of 654 companies
in the Biotechnology industry
Industry Median: 1.745 vs OCSE:ZEAL: 26.42

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Zealand Pharma A/S's adjusted book value per share data for the three months ended in Mar. 2024 was kr45.556. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is kr24.20 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Zealand Pharma A/S Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Zealand Pharma A/S's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zealand Pharma A/S Cyclically Adjusted PB Ratio Chart

Zealand Pharma A/S Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 12.79 10.84 6.62 8.96 16.10

Zealand Pharma A/S Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 9.55 10.85 13.27 16.10 28.16

Competitive Comparison of Zealand Pharma A/S's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Zealand Pharma A/S's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Zealand Pharma A/S's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Zealand Pharma A/S's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Zealand Pharma A/S's Cyclically Adjusted PB Ratio falls into.



Zealand Pharma A/S Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Zealand Pharma A/S's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=639.50/24.2
=26.43

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Zealand Pharma A/S's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Zealand Pharma A/S's adjusted Book Value per Share data for the three months ended in Mar. 2024 was:

Adj_Book=Book Value per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=45.556/118.4000*118.4000
=45.556

Current CPI (Mar. 2024) = 118.4000.

Zealand Pharma A/S Quarterly Data

Book Value per Share CPI Adj_Book
201406 13.229 99.700 15.710
201409 13.974 99.700 16.595
201412 11.173 99.400 13.309
201503 9.244 100.200 10.923
201506 7.103 100.300 8.385
201509 6.788 100.200 8.021
201512 10.603 99.800 12.579
201603 7.495 100.200 8.856
201606 4.486 100.600 5.280
201609 8.535 100.200 10.085
201612 10.876 100.300 12.839
201703 9.875 101.200 11.553
201706 7.084 101.200 8.288
201709 20.824 101.800 24.220
201712 16.772 101.300 19.603
201803 14.243 101.700 16.582
201806 10.305 102.300 11.927
201809 40.423 102.400 46.739
201812 36.334 102.100 42.135
201903 34.316 102.900 39.485
201906 30.449 102.900 35.036
201909 39.362 102.900 45.291
201912 33.167 102.900 38.163
202003 32.948 103.300 37.764
202006 45.299 103.200 51.971
202009 40.036 103.500 45.800
202012 30.887 103.400 35.368
202103 38.522 104.300 43.730
202106 31.848 105.000 35.912
202109 27.471 105.800 30.743
202112 21.469 106.600 23.845
202203 16.422 109.900 17.692
202206 10.951 113.600 11.414
202209 7.913 116.400 8.049
202212 15.852 115.900 16.194
202303 13.004 117.300 13.126
202306 29.649 116.400 30.158
202309 31.163 117.400 31.428
202312 27.285 116.700 27.682
202403 45.556 118.400 45.556

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Zealand Pharma A/S  (OCSE:ZEAL) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Zealand Pharma A/S Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Zealand Pharma A/S's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Zealand Pharma A/S (OCSE:ZEAL) Business Description

Traded in Other Exchanges
Address
Sydmarken 11, Soborg, DNK, DK-2860
Zealand Pharma A/S is a biotechnology company. It is focused on the discovery, design, and development of peptide-based medicines. The company's product pipeline includes three product candidates in clinical development: glepaglutide, which is being developed to treat short bowel syndrome or SBS; dasiglucagon formulated for use in a dual-hormone artificial pancreas system for diabetes management; and dasiglucagon for use in the treatment of congenital hyperinsulinism. The company has out-licensed a peptide program to Boehringer Ingelheim that has been moved ahead into early clinical development: a once-weekly novel dual-acting GLP-1/glucagon agonist for the treatment of obesity and/or Type 2 diabetes.